Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA

Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA

Brian J Lipworth,1 David J Collier,2 Yasuhiro Gon,3 Nanshan Zhong,4 Koichi Nishi,5 Rongchang Chen,4 Samir Arora,6 Andrea Maes,7 Shahid Siddiqui,8 Colin Reisner,7,8 Ubaldo J Martin8 1Scottish Centre for Respiratory Research, Ninewells Hospital, University of Dundee, Dundee, Scotland, UK; 2William Ha...

Full description

Bibliographic Details
Main Authors: Lipworth BJ, Collier DJ, Gon Y, Zhong NS, Nishi K, Chen R, Arora S, Maes A, Siddiqui S, Reisner C, Martin UJ
Format: Article
Language:English
Published: Dove Medical Press 2018-09-01
Series:International Journal of COPD
Subjects:
β2-agonist
Bronchodilator
COPD
Co-suspension delivery technology
Muscarinic antagonist
Online Access:https://www.dovepress.com/improved-lung-function-and-patient-reported-outcomes-with-co-suspensio-peer-reviewed-article-COPD

Internet

https://www.dovepress.com/improved-lung-function-and-patient-reported-outcomes-with-co-suspensio-peer-reviewed-article-COPD

Similar Items